China National Medical Products Administration grants approval of Roche ’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer
Basel, 14 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).“Small cell lung cancer is an area of major unmet need in China and one that has seen limited advances until now,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. “This approval makes Tecentriq the first cancer immunotherapy...
Source: Roche Media News - February 14, 2020 Category: Pharmaceuticals Source Type: news

China National Medical Products Administration grants approval of Roche ’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer
Basel, 14 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).“Small cell lung cancer is an area of major unmet need in China and one that has seen limited advances until now,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. “This approval makes Tecentriq the first cancer immunotherapy...
Source: Roche Investor Update - February 14, 2020 Category: Pharmaceuticals Source Type: news

New connections: Targeted treatment options for SCLC
Various studies reveal how we might effectively treat small cell lung cancer. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - February 11, 2020 Category: Science Authors: Ferrarelli, L. K. Tags: STKE Editors ' Choice Source Type: news

Revealed an alteration related to the loss of effectiveness of a treatment in lung cancer
(Josep Carreras Leukaemia Research Institute) Researchers from IJC reveal that non-smoking patients with lung cancer that have an alteration in RB1 and are treated with EGFR inhibitors, acquire resistance to treatment through the mechanism of histopathological transformation, either to non-small cell lung cancer (SCLC) or SLCL combined with a transformation to squamous cell lung cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 23, 2020 Category: Cancer & Oncology Source Type: news

Imfinzi granted FDA Priority Review for the treatment of patients with extensive-stage small cell lung cancer
AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) and granted Priority Review for Imfinzi (durvalumab) for the treatment of patients with previously untreated extensive-stage small cell lung cancer (SCLC). (Source: World Pharma News)
Source: World Pharma News - November 29, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

European Commission approves Roche ’s Tecentriq in combination with chemotherapy for the initial treatment of people with extensive-stage small cell lung cancer
Roche today announced that the European Commission has approved and granted marketing authorisation for Tecentriq ® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). (Source: Roche Media News)
Source: Roche Media News - September 6, 2019 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Tecentriq in combination with chemotherapy for the initial treatment of people with extensive-stage small cell lung cancer
Roche today announced that the European Commission has approved and granted marketing authorisation for Tecentriq ® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - September 6, 2019 Category: Pharmaceuticals Source Type: news

AbbVie Discontinues Rovalpituzumab Tesirine (Rova-T) Research and Development Program
MERU, a Phase 3 placebo-controlled trial evaluating Rova-T as a first-line maintenance therapy for advanced small-cell lung cancer (SCLC), demonstrated no survival benefit for patients receiving Rova-T at the interim analysis Independent Data Monitoring... Biopharmaceuticals, Oncology AbbVie, Rova-T, Rovalpituzumab Tesirine, small-cell lung cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 29, 2019 Category: Pharmaceuticals Source Type: news

Use of Prophylactic Cranial Irradiation for Extensive-Stage Small-Cell Lung Cancer May Be Dropping Use of Prophylactic Cranial Irradiation for Extensive-Stage Small-Cell Lung Cancer May Be Dropping
Prophylactic cranial irradiation (PCI) for patients with extensive-stage small-cell lung cancer (ES-SCLC) appears to have become less common in the U.S., according to a new survey.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 24, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

CHMP recommends EU approval of Roche ’s Tecentriq in combination with chemotherapy as an initial treatment of adults with extensive-stage small cell lung cancer
Roche today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). (Source: Roche Media News)
Source: Roche Media News - July 26, 2019 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Roche ’s Tecentriq in combination with chemotherapy as an initial treatment of adults with extensive-stage small cell lung cancer
Roche today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - July 26, 2019 Category: Pharmaceuticals Source Type: news

FDA Approves Keytruda (pembrolizumab) for the Treatment of Metastatic Small Cell Lung Cancer (SCLC)
KENILWORTH, N.J.--(BUSINESS WIRE)--June 18, 2019 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, as... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 19, 2019 Category: Drugs & Pharmacology Source Type: news

Dr. Farago on Trilaciclib for Myelosuppression in Previously Treated Extensive-Stage SCLC
Cancer Network spoke with Anna F. Farago, MD, of Massachusetts General Hospital, about the effect of trilaciclib on myelosuppression in patients with previously treated extensive-stage small-cell lung cancer receiving topotecan. (Source: CancerNetwork)
Source: CancerNetwork - June 11, 2019 Category: Cancer & Oncology Authors: Anna F. Farago, MD, PhD Source Type: news

Twice-Daily Radiation for SCLC Tied to Higher Risk of Brain Metastases in Chinese Patients Twice-Daily Radiation for SCLC Tied to Higher Risk of Brain Metastases in Chinese Patients
In patients treated for small-cell lung cancer (SCLC) in China, twice-daily radiotherapy was associated with more brain metastases than once-daily radiation, a retrospective study found.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - June 3, 2019 Category: Pathology Tags: Hematology-Oncology News Source Type: news

Maintenance immunotherapy fails to improve survival in extensive small cell lung cancer
(European Society for Medical Oncology) Maintenance immunotherapy fails to improve survival in extensive-stage small cell lung cancer (SCLC), according to late-breaking results from the CheckMate 451 study to be presented today at the European Lung Cancer Congress (ELCC) 2019. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 11, 2019 Category: Cancer & Oncology Source Type: news

AACR: Pembrolizumab Beneficial for Advanced Small Cell Lung Cancer
Antitumor activity promising; objective response rate 19.3 percent for patients with incurable, advanced SCLC (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 2, 2019 Category: Cancer & Oncology Tags: Oncology, Pulmonology, Conference News, Source Type: news

AACR: Pembrolizumab Beneficial for Advanced Small Cell Lung Cancer
TUESDAY, April 2, 2019 -- For patients with advanced small cell lung cancer (SCLC), pembrolizumab shows antitumor activity with durable responses, according to a study presented at the annual meeting of the American Association for Cancer Research,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 2, 2019 Category: Pharmaceuticals Source Type: news

Data from two KEYNOTE trials show pembrolizumab benefited patients with advanced SCLC
(American Association for Cancer Research) The anti-PD-1 monoclonal antibody pembrolizumab (Keytruda) showed promising antitumor activity with durable responses in patients with pretreated, advanced small cell lung cancer (SCLC), according to results from a pooled analysis of the two clinical trials, the phase 1b KEYNOTE-028 and the phase II KEYNOTE-158, presented at the AACR Annual Meeting 2019, March 29-April 3. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 1, 2019 Category: Cancer & Oncology Source Type: news

Focus on immunotherapy and patient perspective at IASLC 2019 Small Cell Lung Cancer Meeting
(International Association for the Study of Lung Cancer) While non-small cell lung cancer (NSCLC) is the more common form of lung cancer and attracts the lion's share of the research funding, recent developments in small cell lung cancer may be shifting that slightly. In order to capitalize on these recent developments, researchers who focus on small cell lung cancer (SCLC) will gather in New York City at Memorial Sloan Kettering Cancer April 3-5, 2019, for the IASLC 2019 Small Cell Lung Cancer Meeting. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 29, 2019 Category: International Medicine & Public Health Source Type: news

Lung cancer patient channels diagnosis into lifetime activism
(International Association for the Study of Lung Cancer) The Third Biennial IASLC-sponsored Small Cell Lung Cancer Workshop will be held at Memorial Sloan Kettering Cancer Center in New York City, April 3-5, 2019, and will focus on preclinical and clinical advances in small cell lung cancer (SCLC) research. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 21, 2019 Category: Cancer & Oncology Source Type: news

FDA approves Roche's Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). (Source: World Pharma News)
Source: World Pharma News - March 20, 2019 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Tecentriq Approved for Small Cell Lung Cancer
TUESDAY, March 19, 2019 -- Tecentriq (atezolizumab) has been approved by the U.S. Food and Drug Administration to treat adults with extensive-stage small cell lung cancer (ES-SCLC). The drug has been approved as a first-line treatment for the... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 19, 2019 Category: General Medicine Source Type: news

FDA approves Roche ’s Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq ® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). (Source: Roche Media News)
Source: Roche Media News - March 19, 2019 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq ® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - March 19, 2019 Category: Pharmaceuticals Source Type: news

Prophylactic cranial irradiation: Improvements for advanced NSCLC
(NRG Oncology) Prophylactic cranial irradiation (PCI), a technique used to prevent the clinical development of brain metastases, is established as a standard approach for many patients with small cell lung cancer (SCLC) after initial therapy. While studies established that PCI decreases the incidence of brain metastases for patients with locally advanced non-small cell lung cancer (LA-NSCLC), there is no established indication for its use for such NSCLC patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 18, 2019 Category: Cancer & Oncology Source Type: news

Sharp Drop in PCI Use for Extensive-Stage SCLC
(MedPage Today) -- Survey shows rapid adoption of new data, shift toward MRI surveillance (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 13, 2019 Category: American Health Source Type: news

Sharp Drop in Prophylactic Brain Irradiation in SCLC
(MedPage Today) -- Survey shows rapid adoption of new data, shift toward MRI surveillance (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 13, 2019 Category: American Health Source Type: news

Researchers develop human cell-based model to study small cell lung cancer
(Rockefeller University Press) Researchers from Weill Cornell Medicine have used human embryonic stem cells to create a new model system that allows them to study the initiation and progression of small cell lung cancer (SCLC). The study, which will be published February 8, 2019 in the Journal of Experimental Medicine, reveals the distinct roles played by two critical tumor suppressor genes that are commonly mutated in these highly lethal cancers. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - February 8, 2019 Category: Biology Source Type: news

Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition
Small cell lung cancer (SCLC) is a recalcitrant, aggressive neuroendocrine-type cancer for which little change to first-line standard-of-care treatment has occurred within the last few decades. Unlike nonsmall cell lung cancer (NSCLC), SCLC harbors few actionable mutations for therapeutic intervention. Lysine-specific histone demethylase 1A (LSD1 also known as KDM1A) inhibitors were previously shown to have selective activity in SCLC models, but the underlying mechanism was elusive. Here, we found that exposure to the selective LSD1 inhibitor ORY-1001 activated the NOTCH pathway, resulting in the suppression of the transcr...
Source: Signal Transduction Knowledge Environment - February 5, 2019 Category: Science Authors: Augert, A., Eastwood, E., Ibrahim, A. H., Wu, N., Grunblatt, E., Basom, R., Liggitt, D., Eaton, K. D., Martins, R., Poirier, J. T., Rudin, C. M., Milletti, F., Cheng, W.-Y., Mack, F., MacPherson, D. Tags: STKE Research Articles Source Type: news

Patients With Lower-Stage Small-Cell Lung Cancer Do Better Patients With Lower-Stage Small-Cell Lung Cancer Do Better
Patients with stage I to II small-cell lung cancer (SCLC) treated with chemoradiotherapy have better outcome than those with stage III disease, according to a secondary analysis of a randomized clinical trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 14, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

FDA grants priority review to Roche's Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of people with extensive-stage small cell lung cancer (ES - SCLC). (Source: World Pharma News)
Source: World Pharma News - December 6, 2018 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Roche's Tecentriq wins speedy U.S. review in small cell lung cancer
Roche's Tecentriq immunotherapy with chemotherapy won priority review in the United States for the initial treatment of extensive-stage small cell lung cancer (SCLC), the company said, setting up possible approval by March 18. (Source: Reuters: Health)
Source: Reuters: Health - December 5, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

FDA grants priority review to Roche ’s Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of people with extensive-stage small cell lung cancer (ES - SCLC). (Source: Roche Media News)
Source: Roche Media News - December 5, 2018 Category: Pharmaceuticals Source Type: news

FDA grants priority review to Roche ’s Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of people with extensive-stage small cell lung cancer (ES - SCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - December 5, 2018 Category: Pharmaceuticals Source Type: news

Age Just a Number for Older, Fit Limited-Stage SCLC Patients
(MedPage Today) -- Standard chemoradiotherapy proved just as effective compared with younger patients (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 9, 2018 Category: Hematology Source Type: news

Concurrent chemo-radiotherapy should be a treatment option for elderly patients with LS-S
(International Association for the Study of Lung Cancer) Elderly patients with limited-stage small cell lung cancer (LS-SCLC) showed similar survival and toxicity compared to their younger counterparts when treated with concurrent chemo-radiotherapy. Concurrent chemo-radiotherapy should be a treatment option for fit patients aged 70 years or older. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 1, 2018 Category: Cancer & Oncology Source Type: news

Nanopore technology with DNA computing easily detects microRNA patterns of lung cancer
(Tokyo University of Agriculture and Technology) Researchers at Tokyo University of Agriculture and Technology (TUAT) have developed a simple technique that allows detection of two independent microRNAs as an early diagnosis marker of Small Cell Lung Cancer (SCLC) , which is very aggressive. In this technique, they combined nanopore and DNA computing technologies as rapid and label-free detection. This method, therefore, could help to identify SCLC in the early stage. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 5, 2018 Category: Cancer & Oncology Source Type: news

Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage
The use of potent therapies inhibiting critical oncogenic pathways active in epithelial cancers has led to multiple resistance mechanisms, including the development of highly aggressive, small cell neuroendocrine carcinoma (SCNC). SCNC patients have a dismal prognosis due in part to a limited understanding of the molecular mechanisms driving this malignancy and the lack of effective treatments. Here, we demonstrate that a common set of defined oncogenic drivers reproducibly reprograms normal human prostate and lung epithelial cells to small cell prostate cancer (SCPC) and small cell lung cancer (SCLC), respectively. We ide...
Source: ScienceNOW - October 4, 2018 Category: Science Authors: Park, J. W., Lee, J. K., Sheu, K. M., Wang, L., Balanis, N. G., Nguyen, K., Smith, B. A., Cheng, C., Tsai, B. L., Cheng, D., Huang, J., Kurdistani, S. K., Graeber, T. G., Witte, O. N. Tags: Medicine, Diseases reports Source Type: news

Roche ’s Tecentriq in combination with chemotherapy helped people live significantly longer as an initial treatment for people with extensive-stage small cell lung cancer
Roche today announced positive results from the Phase III IMpower133 study of Tecentriq ® (atezolizumab) plus carboplatin and etoposide (chemotherapy) for the initial (first-line) treatment of people with previously-untreated extensive-stage small cell lung cancer (ES-SCLC). (Source: Roche Media News)
Source: Roche Media News - September 25, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with chemotherapy helped people live significantly longer as an initial treatment for people with extensive-stage small cell lung cancer
Roche today announced positive results from the Phase III IMpower133 study of Tecentriq ® (atezolizumab) plus carboplatin and etoposide (chemotherapy) for the initial (first-line) treatment of people with previously-untreated extensive-stage small cell lung cancer (ES-SCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - September 25, 2018 Category: Pharmaceuticals Source Type: news

FDA Approves Nivolumab (Opdivo) for Small Cell Lung Cancer FDA Approves Nivolumab (Opdivo) for Small Cell Lung Cancer
The new approval is accelerated and is therefore conditional upon further proof of efficacy, but the checkpoint inhibitor becomes the first approved option in advanced SCLC in a long time.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 17, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

BMS gets FDA ok for first new SCLC med in 20 years
Bristol-Myers Squibb announced that the U.S. FDA has approved Opdivo as a treatment for certain patients with previously treated small cell lung cancer. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - August 17, 2018 Category: Pharmaceuticals Source Type: news

Researchers discover new vulnerability in deadly form of lung cancer
(UT Southwestern Medical Center) Researchers at the Children's Medical Center Research Institute at UT Southwestern (CRI) have discovered a new metabolic vulnerability in small cell lung cancer (SCLC) that can be targeted by existing drug therapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 3, 2018 Category: Cancer & Oncology Source Type: news

Researchers discover a new type of lung cancer
(Cold Spring Harbor Laboratory) Researchers have discovered a new kind of small-cell lung cancer (SCLC). The discovery paves the way for developing personalized medicine approaches to target this previously unnoticed form of the disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 25, 2018 Category: Cancer & Oncology Source Type: news

PARP Inhibitor Active in SCLC Subgroup
(MedPage Today) -- Better OS seen among those expressing marker of DNA damage (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 23, 2018 Category: Hematology Source Type: news

PARP inhibitor improves overall response rates in small cell lung cancer patients
(University of Texas M. D. Anderson Cancer Center) In a randomized, Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center, adding the PARP inhibitor veliparib to a standard chemotherapy agent improved overall response rates (ORR) in patients with small cell lung cancer (SCLC). Researchers also identified a select group of patients -- those whose tumors expressed SLFN11 -- who also saw a progression-free survival (PFS) and overall survival (OS) benefit, suggesting a promising biomarker for the PARP-inhibitor sensitivity in SCLC. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 11, 2018 Category: International Medicine & Public Health Source Type: news

Evolving Use of ICIs and Targeted Tx in NSCLC and SCLC
In this video,Apar Ganti, MD, highlights recent advances and studies presented at ASCO 2018 on management of NSCLC and SCLC with ICIs and targeted agents. (Source: CancerNetwork)
Source: CancerNetwork - June 9, 2018 Category: Cancer & Oncology Authors: Apar Kishor Ganti, MD, MS Source Type: news

Targeting DNA Repair in SCLC and the Biomarker Landscape Targeting DNA Repair in SCLC and the Biomarker Landscape
Areas of investigation for SCLC include identification of predictive biomarkers, effective combinations to overcome resistance, and strategies for immunotherapy.Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 16, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

New liquid biopsy-based cancer model reveals data on deadly lung cancer
(University of Texas M. D. Anderson Cancer Center) Small cell lung cancer (SCLC) accounts for 14 percent of all lung cancers and is often rapidly resistant to chemotherapy resulting in poor clinical outcomes. Treatment has changed little for decades, but a study at The University of Texas MD Anderson Cancer Center offers a potential explanation for why the disease becomes chemoresistant, and a possible avenue to explore new diagnostic approaches. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 15, 2018 Category: Cancer & Oncology Source Type: news

Current Standards for Clinical Management of SCLC Current Standards for Clinical Management of SCLC
Review the latest on diagnosis, staging, and management of SCLC.Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 15, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news